Key Takeaways Illumina said it would take a $1.47 billion goodwill impairment charge related to its spinoff of cancer testing company GRAIL. Illumina also said it would take a$420 million charge for GRAIL's in-process R&D. Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years. The breakup with GRAIL (GRAL) was costly for Illumina (ILMN). The gene sequencing company wrote in a regulatory filing Thursday that it would take a $1.47 billion goodwill impairment char ...